Clinical Trials Browser

Withdrawn × INDUSTRY × Erlotinib Hydrochloride × Clear all

NCT03529084 2019-11-22

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02034097 2014-05-19

A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00754104 2011-01-19

Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors

Phase 1 Withdrawn

Other solid neoplasm

Solid Tumors